Your session is about to expire
← Back to Search
Brachytherapy
Ultra-Hypofractionated Radiotherapy + Brachytherapy for Prostate Cancer (HYPO-5 Trial)
N/A
Recruiting
Research Sponsored by CHU de Quebec-Universite Laval
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up at 5 years
Awards & highlights
HYPO-5 Trial Summary
This trial will compare two different radiation therapies for prostate cancer, looking at toxicity, acceptability, and long-term success rates.
Who is the study for?
Men with early-stage prostate cancer (Stage T1c or T2), no spread to lymph nodes or distant organs, PSA levels below 20ng/ml, and a Gleason Score of 6 or 7. Participants must be able to give written consent. Excluded are those with advanced disease stages, high Gleason Scores (8-10), severe urinary symptoms, prior pelvic radiotherapy, bilateral hip prosthesis, under age 18, inflammatory bowel disease history, or active collagen diseases.Check my eligibility
What is being tested?
This Phase 1-2 study compares two types of radiation therapy for prostate cancer: ultra-hypofractionnated versus moderately hypofractionnated therapy combined with image-guided HDR brachytherapy. The goal is to determine if the shorter treatment is just as safe as the longer one in terms of side effects over time.See study design
What are the potential side effects?
Potential side effects include typical reactions from radiation such as skin irritation near the treated area, fatigue during and after treatment sessions, urinary issues like discomfort or frequency increase and potential bowel changes.
HYPO-5 Trial Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ at 5 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~at 5 years
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
GI toxicity analysis (CTCAE)
GU toxicity analysis (CTCAE)
quality of life questionnaires analysis (EPIC26)
+2 moreSecondary outcome measures
Clinical outcomes
HYPO-5 Trial Design
2Treatment groups
Experimental Treatment
Active Control
Group I: ultra hypo fractionation radiation therapyExperimental Treatment1 Intervention
comparative PRO's of 25 Gy in 5 daily fractions (Ultra hypo fractionation) administered to prostate and 1st centimeter of proximal seminal vesicle, starting mid week and ending mid following week.
Group II: moderate hypo fractionation radiation therapyActive Control1 Intervention
PRO's of moderate hypo fractionation, 37,5 Gy in 15 or 36 Gy in 12 daily fractions administered 5 days per week.
Find a Location
Who is running the clinical trial?
CHU de Quebec-Universite LavalLead Sponsor
167 Previous Clinical Trials
106,952 Total Patients Enrolled
12 Trials studying Prostate Cancer
3,637 Patients Enrolled for Prostate Cancer
Andre-Guy MartinStudy ChairCHU de Québec
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I have had radiation therapy to my pelvic area before.I have a history of autoimmune diseases like Lupus.I have a history of inflammatory bowel disease.My cancer has spread to nearby lymph nodes.My IPSS score is over 20 despite being on medication for urinary symptoms.My cancer is in a late stage, but has not spread to distant organs.I am under 18 years old.My cancer has not spread to distant parts of my body.My prostate cancer has a Gleason score of 6 or 7.I can sign a consent form.My prostate cancer was confirmed through a biopsy.My cancer is at an early stage, but not the earliest.My cancer has not spread to nearby lymph nodes.My prostate cancer is aggressive (Gleason Score 8-10).My cancer has spread to other parts of my body.
Research Study Groups:
This trial has the following groups:- Group 1: ultra hypo fractionation radiation therapy
- Group 2: moderate hypo fractionation radiation therapy
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Does this research accept participants of a younger age demographic?
"This medical study is open to all individuals aged 18 years and above, up to the age of 95."
Answered by AI
Who qualifies for participation in this research trial?
"Aspiring participants must be between 18 and 95 years of age, have been diagnosed with prostate cancer, and meet the other criteria set forth by this trial. 205 individuals are required to complete it successfully."
Answered by AI
Is enrollment in this scientific experiment still open?
"Affirmative, records from clinicaltrials.gov demonstrate that this medical trial is presently accepting participants. It was first listed on April 1st 2014 and last updated on March 14th 2023; 205 volunteers are necessary across one site."
Answered by AI
How many volunteers are participating in this research endeavor?
"Affirmative, based on information published on clinicaltrials.gov this medical study is currently recruiting patients. This trial was initially listed April 1st 2014 and was most recently modified March 14th 2023. Currently, 205 volunteers are needed from a single site to participate in the experiment."
Answered by AI
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger